Initial in vivo quantification of Tc-99m Sestamibi uptake as a function of tissue type in healthy breasts using dedicated breast SPECT-CT

26Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A pilot study is underway to quantify in vivo the uptake and distribution of Tc-99m Sestamibi in subjects without previous history of breast cancer using a dedicated SPECT-CT breast imaging system. Subjects undergoing diagnostic parathyroid imaging studies were consented and imaged as part of this IRB-approved breast imaging study. For each of the seven subjects, one randomly selected breast was imaged prone-pendant using the dedicated, compact breast SPECT-CT system underneath the shielded patient support. Iteratively reconstructed and attenuation and/or scatter corrected images were coregistered; CT images were segmented into glandular and fatty tissue by three different methods; the average concentration of Sestamibi was determined from the SPECT data using the CT-based segmentation and previously established quantification techniques. Very minor differences between the segmentation methods were observed, and the results indicate an average image-based in vivo Sestamibi concentration of 0.10 ± 0.16 μCi/mL with no preferential uptake by glandular or fatty tissues. © 2012 Steve D. Mann et al.

Cite

CITATION STYLE

APA

Mann, S. D., Perez, K. L., McCracken, E. K. E., Shah, J. P., Wong, T. Z., & Tornai, M. P. (2012). Initial in vivo quantification of Tc-99m Sestamibi uptake as a function of tissue type in healthy breasts using dedicated breast SPECT-CT. Journal of Oncology. https://doi.org/10.1155/2012/146943

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free